In-Tumor Biosynthetic Construction of Upconversion Nanomachines for Precise Near-Infrared Phototherapy
Citations Over TimeTop 14% of 2023 papers
Abstract
Targeted construction of therapeutic nanoplatforms in tumor cells with specific activation remains appealing but challenging. Here, we design a cancer-motivated upconversion nanomachine (UCNM) based on porous upconversion nanoparticles (p-UCNPs) for precise phototherapy. The nanosystem is equipped with a telomerase substrate (TS) primer and simultaneously encapsulates 5-aminolevulinic acid (5-ALA) and d-arginine (d-Arg). After coating with hyaluronic acid (HA), it can readily get into tumor cells, where 5-ALA induces efficient accumulation of protoporphyrin IX (PpIX) via the inherent biosynthetic pathway, and the overexpressed telomerase prolonged the TS to form G-quadruplexes (G4) for binding the resulting PpIX as a nanomachine. This nanomachine can respond to near-infrared (NIR) light and promote the active singlet oxygen (1O2) production due to the efficiency of Förster resonance energy transfer (FRET) between p-UCNPs and PpIX. Intriguingly, such oxidative stress can oxidize d-Arg into nitric oxide (NO), which relieves the tumor hypoxia and in turn improves the phototherapy effect. This in situ assembly approach significantly enhances targeting in cancer therapy and might be of considerable clinical value.
Related Papers
- → In-vivo singlet oxygen dosimetry of clinical 5-aminolevulinic acid photodynamic therapy(2008)39 cited
- → Design of novel photosensitizers and controlled singlet oxygen generation for photodynamic therapy(2021)11 cited
- → Mitochondria as the target organelle for protoporphyrin IX (PPIX) accumulation and toxicity in photodynamic diagnosis (PDD) and photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA)(2001)
- → Benefits and Problems of Photodynamic Diagnosis in Brain Tumor Treatment(2020)
- → Mitochondria as the target organelle for protoporphyrin IX (PPIX) accumulation and toxicity in photodynamic diagnosis (PDD) and photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA)(2001)